Clinical trials: Gastrooesophageal Cancer
Urothelial Cancer, GastroEsophageal Cancer
A Study of MGC030 in Participants With Advanced Solid Tumors
The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of MGC030.
- Conditions
- Urothelial Cancer, GastroEsophageal Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT07822399
- Testing
- MGC030
- Where
- United States
- Volunteers
- 314 people
- Sponsor
- MacroGenics
Gastroesophageal Cancer, Immune Checkpoint Inhibition
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
This is a Phase 1B study assessing the safety of immune checkpoint inhibition after SBRT in patients with recurrent or metastatic gastroesophageal cancer (limited metastatic disease).
- Trial name
- REACTION (NCT03610711)
- Testing
- Nivolumab, Relatlimab
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gastric Cancer
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer
This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative adenocarcinoma of the…
- Trial name
- NCT01590719
- Testing
- Onartuzumab (MetMAb), Oxaliplatin, Folinic acid
- Where
- 36 sites in United States, Australia and 4 more
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Advanced Gastroesophageal Cancer
Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With Immunochemotherapy
This study is a prospective, randomized, parallel-controlled, multicenter clinical study. The purpose of this study is to evaluate the efficacy and safety of nanocrystalline megestrol acetate combined with the first-line standard…
- Trial name
- NCT06963593
- Testing
- Nanocrystal Megestrol Acetate in Combination with First-Line Standard Immuno-Chemotherapy Regimen, First-Line Standard Immuno-Chemotherapy Regimen
- Volunteers
- 220 people
- Sponsor
- Peking University
GastroEsophageal Cancer
Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)
The goal of this observational study is to examine genetic changes that may contribute to immunotherapy resistance in gastroesophageal cancer.
- Trial name
- NCT06283238
- Testing
- Immune checkpoint inhibitor (ICI) or chemotherapy alone
- Where
- United States
- Sponsor
- Duke University
GastroEsophageal Cancer
A Systems Approach to Immunotherapy Biomarker Identification Within the Postoperative Wound-Healing Microenvironment in Patients With Gastroesophageal Cancer
The purpose of this research is to collect surgical drain fluid and blood from patients who have undergone surgery for gastric or esophageal cancer, and to analyze the fluid and blood using a variety of laboratory techniques for…
- Trial name
- BAISIC (NCT05338060)
- Testing
- prospective collection of surgical exudates (SEs)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Inova Health Care Services
Esophageal Cancer, Gastric Cancer
Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer
- Trial name
- NCT00439608
- Testing
- Cetuximab,Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Brown University
Gastroesophageal Cancer, Gastric Cancer
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
This is a Phase II open-label study to determine the anti-tumor efficacy and tolerability of FOLFOX in combination with bevacizumab (Avastin(TM))in patients with metastatic or unresectable gastroesophageal and gastric…
- Trial name
- NCT00673673
- Testing
- FOLFOX, bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Yale University
Gastric Cancer, GastroEsophageal Cancer
Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
ROSETTE trial is an open-label, randomized phase II study designed to investigate treatment strategies for patients with limited metastatic gastric or gastroesophageal adenocarcinoma.
- Trial name
- ROSETTE (NCT06468280)
- Testing
- Local treatment (Surgical), PD-1 Monoclonal Antibody, XELOX/SOX Chemotherapy Regimen
- Where
- 2 sites in China
- Volunteers
- 84 people
- Sponsor
- Shanghai Zhongshan Hospital
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with…
- Conditions
- Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck
- Trial name
- NCT04504669
- Testing
- AZD8701, Durvalumab
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Gastric Cancer, GastroEsophageal Cancer
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
This is a randomized, open-label, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus capecitabine and oxaliplatin sequenced by SHR-1210 plus apatinib versus capecitabine and oxaliplatin as…
- Trial name
- NCT03813784
- Testing
- SHR-1210, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 885 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Esophageal Cancer, Gastric Cancer
Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00524186
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Roswell Park Cancer Institute
Esophageal Carcinoma, Gastroesophageal Junction Carcinoma
A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
The purpose of this study is to describe the effectiveness and use of nivolumab after surgery in participants with early stage (Stage II/III) Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC).
- Trial name
- PROSPECT-ESO (NCT05780736)
- Where
- 24 sites in United States, Germany
- Volunteers
- 33 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Esophageal Cancer, Gastric Cancer
Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00020787
- Testing
- G17DT Immunogen, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Gastroesophageal Cancer
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma.
- Trial name
- TroFuse-015 (NCT06356311)
- Testing
- Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan
- Where
- 168 sites in United States, Belgium and 22 more
- Volunteers
- 473 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Cancer, HER2-positive Gastric Cancer
Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
TRINITY is designed as a multicentre, randomized, open-label, interventional phase II study aimed at investigating the activity, efficacy and safety of trastuzumab-deruxtecan (T-DXd) plus capecitabine/5-fluorouracil as a…
- Trial name
- TRINITY (NCT06253650)
- Testing
- Experimental, Control
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Adenocarcinoma of the Stomach, GastroEsophageal Cancer
Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer
Patients with Her2 negative, previously untreated metastatic esophagogastric adenocarcinoma will be treated with modified FOLFOX, with modified FOLFOX plus Nivolumab and Ipilimumab or FLOT plus Nivolumab.
- Trial name
- NCT03647969
- Testing
- Nivolumab, Ipilimumab, mFOLFOX
- Where
- 27 sites in Germany
- Volunteers
- 262 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Solid Tumors
Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer
Claudiximab is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. Preclinically, claudiximab was shown to inhibit tumor growth and to kill cancer cells by indirect (complement-dependent cytoxicity…
- Trial name
- NCT00909025
- Testing
- Claudiximab
- Where
- 6 sites in Germany, Latvia
- Volunteers
- 15 people
- Sponsor
- Ganymed Pharmaceuticals GmbH
Esophageal Cancer, Stomach Cancer
Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer
The survival of esophageal cancer and stomach cancer (EGC) at 5 years is less than 30%. Pravastatin is a potent inhibitor of HMG-CoA reductase inhibitor that has shown increased survival in patients with advanced hepatocellular…
- Trial name
- AGIM-1 (NCT01038154)
- Testing
- Pravastatin
- Where
- Spain
- Volunteers
- 146 people
- Sponsor
- Hospital Donostia